Loading clinical trials...

Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung | Clinical Trials | Clareo Health

COMPLETEDNA

Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung

An Efficacy and Feasibility Study to Investigate the Effect of Ectoin® Inhalation Solution (EIL) in Subjects With Inflammation and Airway Obstruction Followed by a Long Term Study Extension on the Prevention of Lung Function Decline

NCT01225965•Bitop AG

View on ClinicalTrials.gov

Summary

To investigate the physical inflammation inhibition effects of EIL (Ectoin-Hydro-Complex) in subjects of the established SALIA-cohort and the preventive effects on lung function decline.

Eligibility

Age

75 - 80 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Postmenopausal females (75 - 80 years)
•FEV1/FVC \< 0,77 (in the investigation 2007/2008)
•Inflammatory markers TFN-alpha \> median or neutrophilic granulocytes \> median (investigation 2007/2008)
•Non smokers or ex smokers who have stopped smoking for longer than 6 months

Exclusion Criteria

•Participation in another clinical study in the previous month
•Severe concomitant disease which may have an impact on the study participation
•Hypersensitivity against Ectoin
•Myocardial infarction or apoplexy within the last year
•Uncontrolled hypertension: systolic blood pressure \>200 mmHg or diastolic pressure \>120 mmHg
•Known aortic aneurysm
•Other respiratory diseases (e.g. cystic fibrosis, alpha-1-Antitrypsin deficiency, sarcoidosis, allergic alveolitis, tuberculosis, etc.)
•Patients who have had treatment with live attenuated vaccinations within 14 days prior to screening visit (Inactivated influenza vaccination is acceptable, provided it is not administered within 7 days prior to screening visit)
•on investigators decision

Locations (1)

Institut für umweltmedizinische Forschung

Düsseldorf, Germany

Key Dates

Start Date

October 1, 2010

Primary Completion Date

February 1, 2011

Completion Date

September 1, 2011

Last Updated

January 29, 2026

Enrollment

ACTUAL participants

Conditions

COPDParticulate Matter Induced Inflammation of the Lung

Interventions

Ectoin Inhalation Solution

DEVICE

Placebo

DEVICE

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGNA

Effect of Telenursing on Oral Health

NCT07462221

COPD

View study

RECRUITINGNA

Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD

NCT07351929

COPD Exacerbation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

Effect of Telenursing on Oral Health

Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD

Probiotics in Pulmonaty Rehabilitation for COPD

Effects of Eccentric Exercise Training in Patients With COPD

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3